AtaiBeckley (ATAI) Net Equity Issued and Repurchased (2021)

AtaiBeckley (ATAI) reported Net Equity Issued and Repurchased of $257.7 million for Q2 2021, up 69.31% sequentially from $152.2 million in Q1 2021.

AtaiBeckley (ATAI) Net Equity Issued and Repurchased (2021) Analysis & Trends

AtaiBeckley (ATAI) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $257.7 million in Q2 2021.

For the quarter ending Q2 2021, Net Equity Issued and Repurchased changed N/A year-over-year to $257.7 million; the trailing twelve-month figure through Mar 2022 stood at $257.7 million (changed N/A YoY), and the FY2021 full-year result was $409.9 million, up 397.2% from the prior year.
Net Equity Issued and Repurchased advanced to $257.7 million in Q2 2021, from $152.2 million in the prior quarter.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $257.7 million in Q2 2021 to a low of $152.2 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	163.10 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	141.90 Mn
10	AtaiBeckley	1.56 Bn	1.56 Bn	-	-

Download Data